Clinical implication and mitotic effect of CD44 cleavage in relation to osteopontin/CD44 interaction and dysregulated cell cycle protein in gastrointestinal stromal tumor

Annals of Surgical Oncology

Volumn 17, Issue 8, 2010, Pages 2199-2212

  Hsu, Kai Hsi ^a,b   Tsai, Hung Wen ^a   Lin, Pin Wen ^a   Hsu, Yun Shang ^c   Shan, Yan Shen ^d   Lu, Pei Jung ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b Tainan Hospital   (Taiwan)

^c SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CELL CYCLE PROTEIN; CYCLIN D1; HERMES ANTIGEN; OSTEOPONTIN;

ADULT; ARTICLE; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MITOSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INTERACTION; TUMOR RECURRENCE; TUMOR VOLUME; WESTERN BLOTTING; AGED; FOLLOW UP; GASTROINTESTINAL STROMAL TUMORS; METABOLISM; MIDDLE AGED; PROGNOSIS;

AGED; ANTIGENS, CD44; BETA CATENIN; BLOTTING, WESTERN; CYCLIN D1; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MITOSIS; OSTEOPONTIN; PROGNOSIS;

EID: 77954958029     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-0927-1     Document Type: Article

References (45)

1. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-65. (Pubitemid 34747864)
2. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science. 1998;279:577-80. (Pubitemid 28067289)
3. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-10.
4. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813-25.
5. Hsu KH, Yang TM, Shan YS, Lin PW. Tumor size is a major determinant of recurrence in patients with resectable gastroin-testinal stromal tumor. Am J Surg. 2007;194:148-52.
6. Keun Park C, Lee EJ, Kim M, Lim HY, Choi DI, Noh JH, et al. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg. 2008;247:1011-8.
7. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241-319.
8. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007;104:10158-63.
9. Du L, Wang H, He L, Zhang J, Ni B, Wang X, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008;14:6751-60.
10. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996;271:509-12.
11. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem. 2001;276:46024-30.
12. Teramoto H, Castellone MD, Malek RL, Letwin N, Frank B, Gutkind JS, et al. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene. 2005;24:489-501.
13. Rittling SR, Chambers AF. Role of osteopontin in tumour pro-gression. Br J Cancer. 2004;90:1877-81.
14. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004;10:184-90.
15. Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic sig-nificance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol. 2007;14:3419-27. (Pubitemid 350160128)
16. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004;95:930-5.
17. Takeda M, Ogino S, Umemoto R, Sakakura M, Kajiwara M, Sugahara KN, et al. Ligand-induced structural changes of the CD44 hyaluronan-binding domain revealed by NMR. J Biol Chem. 2006;281:40089-95.
18. Pelletier L, Guillaumot P, Freche B, Luquain C, Christiansen D, Brugière S, et al. Gamma-secretase-dependent proteolysis of CD44 promotes neoplastic transformation of rat fibroblastic cells. Cancer Res. 2006;66:3681-7.
19. Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol. 2002;160:441-7.
20. Takamune Y, Ikebe T, Nagano O, Nakayama H, Ota K, Obayashi T, et al. ADAM-17 associated with CD44 cleavage and metas-tasis in oral squamous cell carcinoma. Virchows Arch. 2007;450:169-77.
21. Hsu KH, Tsai HW, Shan YS, Lin PW. Significance of CD44 expression in gastrointestinal stromal tumors in relation to disease progression and survival. World J Surg. 2007;31:1438-44.
22. Kothapalli D, Zhao L, Hawthorne EA, Cheng Y, Lee E, Puré E, et al. Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells. J Cell Biol. 2007;176:535-44.
23. Kothapalli D, Flowers J, Xu T, Puré E, Assoian RK. Differential activation of ERK and Rac mediates the proliferative and anti-proliferative effects of hyaluronan and CD44. J Biol Chem. 2008;283:31823-9.
24. Gehrke I, Gandhirajan RK, Kreuzer KA. Targeting the WNT/beta-catenin/TCF/ LEF1 axis in solid and haematological cancers: multiplicity of therapeutic options. Eur J Cancer. 2009;45:2759-67.
25. Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci. 2008;121:3853-7.
26. Söderberg O, Leuchowius KJ, Gullberg M, Jarvius M, Weibrecht I, Larsson LG, et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods. 2008;45:227-32.
27. Cuff CA, Kothapalli D, Azonobi I, Chun S, Zhang Y, Belkin R, et al. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell acti-vation. J Clin Invest. 2001;108:1031-40.
28. Yamaguchi J, Sawada N, Tobioka H, Takakuwa R, Goto T, Sakuma Y, et al. Electron microscopic and immunohistochemical studies of gastrointestinal stromal tumors. Med Electron Microsc. 1999;32:213-20.
29. Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, et al. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer. 2006;106:1617-23.
30. Barboule N, Demeter K, Benmeradi N, Larminat F. Bcl-2 is an integral component of mitotic chromosomes. Cell Biol Int. 2009;33:572-7.
31. Furth PA, Bar-Peled U, Li M, Lewis A, Laucirica R, Jäger R, et al. Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model. Oncogene. 1999;18:6589-96.
32. Massagué J. G1 cell-cycle control and cancer. Nature. 2004;432:298-306.
33. Musgrove EA. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors. 2006;24:13-9.
34. Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, et al. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol. 2005;36:828-37.
35. Sabah M, Cummins R, Leader M, Kay E. Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: markers with potential prognostic implications. Hum Pathol. 2006;37:648-55.
36. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006;66:4553-7.
37. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene. 2004;23:7274-82.
38. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007;104:973-8.
39. Pazolli E, Luo X, Brehm S, Carbery K, Chung JJ, Prior JL, et al. Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res. 2009;69:1230-9.
40. Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem. 2006;281:5861-8.
41. Murai T, Miyauchi T, Yanagida T, Sako Y. Epidermal growth factor-regulated activation of Rac GTPase enhances CD44 cleavage by metalloproteinase disintegrin ADAM10. Biochem J. 2006;395:65-71.
42. Sugahara KN, Hirata T, Tanaka T, Ogino S, Takeda M, Terasawa H, et al. Chondroitin sulfate E fragments enhance CD44 cleavage and CD44-dependent motility in tumor cells. Cancer Res. 2008;68:7191-9.
43. Raheja LF, Genetos DC, Yellowley CE. Hypoxic osteocytes recruit human MSCs through an OPN/CD44-mediated pathway. Biochem Biophys Res Commun. 2008;366:1061-6.
44. Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, et al. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res. 2008;14:7470-80.
45. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007;26:6361-71.